|
Federal
Register Notices > Notices of
Application - 2000 > Radian International LLC
[Federal Register: May 23, 2000 (Volume 65, Number
100)]
[Notices]
[Page 33354-33355]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23my00-100]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of
Application
Pursuant to Section 1301.33(a) of Title 21 of the
Code of Federal Regulations (CFR), this is notice that on March 30,
2000, Radian International LLC, 14050 Summit Drive #121, P.O. Box
201088, Austin, Texas 78720-1088, made application by renewal to the
Drug Enforcement Administration (DEA) for registration as a bulk
manufacturer of the basic classes of controlled substances listed below:
| Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| N-Ethylamphetamine (1475) |
I |
| N-N-Dimethylamphetamine (1480) |
I |
| Aminorex (1585) |
I |
| 4-Methylaminorex (cis isomer)
(1590) |
I |
| Methaqualone (2565) |
I |
| Alpha-Ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide
(7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| Mescaline (7381) |
I |
| 3,4,5-Trimethoxyamphetamine
(7390) |
I |
| 4-Bromo-2,5-dimethoxyamphetamine
(7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine
(7392) |
I |
| 4-Methyl-2,5-dimethoxyamphetamine
(7395) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 2,5-Dimethoxy-4-ethylamphetamine
(7399) |
I |
| 3,4-Methylenedioxyamphetamine
(7400) |
I |
| 5-Methoxy-3,4-methylenedioxyamphetamine
(7401) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine
(7402) |
I |
| 3,4-Methylenedioxy-N-ethylamphetamine
(7404) |
I |
| 3,4-Methylenedioxymethamphetamine
(7405) |
I |
| 4-Methoxyamphetamine (7411) |
I |
| Bufotenine (7433) |
I |
| Diethyltryptamine (7434) |
I |
| Dimethyltryptamine (7435) |
I |
| Psilocybin (7437) |
I |
| Psilocyn (7438) |
I |
| Acetyldihydrocodeine (9051) |
I |
| Benzylmorphine (9052) |
I |
| Codeine-N-oxide (9053) |
I |
| Dihydromorphine (9145) |
I |
| Heroin (9200) |
I |
| Morphine-N-oxide (9307) |
I |
| Normorphine (9313) |
I |
| Pholcodine (9314) |
I |
| Acetylmethadol (9601) |
I |
| Allyprodine (9602) |
I |
| Alphacetylmethadol except
Levo-Alphacetylmethadol (9603) |
I |
| Alphameprodine (9604) |
I |
| Alphamethadol (9605) |
I |
| Betacetylmethadol (9607) |
I |
| Betameprodine (9608) |
I |
| Betamethadol (9609) |
I |
| Betaprodine (9611) |
I |
| Hydromorphinol (9627) |
I |
| Noracymethadol (9633) |
I |
| Norlevorphanol (9634) |
I |
| Normethadone (9635) |
I |
| Trimeperidine (9646) |
I |
| Para-Fluorofentanyl (9812) |
I |
| 3-Methylfentanyl (9813) |
I |
| Alpha-methylfentanyl (9814) |
I |
| Acetyl-alpha-methylfentanyl
(9815) |
I |
| Beta-hydroxyfentanyl (9830) |
I |
| Beta-hydroxy-3-methyfentanyl
(9831) |
I |
| Alpha-Methylthiofentanyl (9832) |
I |
| 3-Methylthiofentanyl (9833) |
I |
| Thiofentanyl (9835) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Phenmetrazine (1631) |
II |
| Methylphenidate (1724) |
II |
| Amobarbital (2125) |
II |
| Pentobarbital (2270) |
II |
| Secobarbital (2315) |
II |
| [[Page 33355]] |
|
| Glutethimide (2550) |
II |
| Nabilone (7379) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| 1-Piperid-inocyclohexanecarbonitrile
(8603) |
II |
| Alphaprodine (9010) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Oxycodone (9143) |
II |
| Hydromorphone (9150) |
II |
| Diphenoxylate (9170) |
II |
| Benzoylecgonine (9180) |
II |
| Ethylmorphine (9190) |
II |
| Hydrocodone (9193) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220) |
II |
| Isomethadone (9226) |
II |
| Meperidine (9230) |
II |
| Methadone (9250) |
II |
| Methadone-intermediate (9254) |
II |
| Morphine (9300) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Oxymorphone (9652) |
II |
| Alfentanil (9737) |
II |
| Sufentanil (9740) |
II |
| Fentanyl (9801) |
II |
The firm plans to manufacture small quantities of
the listed controlled substances to make deuterated and nondeuterated
drug reference standards which will be distributed to analytical and
forensic laboratories for drug testing programs.
Any other such applicant and any person who is
presently registered with DEA to manufacture such substances may file
comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed,
in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, United States
Department of Justice, Washington, D.C. 20537, Attention: DEA Federal
Register Representative (CCR), and must be filed no later than July 24,
2000.
Dated: May 11, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 00-12844 Filed 5-22-00; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
Back to
Top
Registration
Support
Toll Free Number: 1-800-882-9539
ARCOS
| Career Opportunities | Chemical Program |
Controlled
Substance Schedules | Drugs and
Chemicals of Concern
Electronic Commerce Initiatives | | Federal Register
Notices | Import Export | Links
| Meetings
and Events | NFLIS
Offices &
Directories | On-Line Forms & Applications |
Program
Description | Publications
|
Questions & Answers | Quotas
Reports Required by 21 CFR | Title 21 Regulations & Codified
CSA
Contact Us | Home
| Hot
Items | Site Map | Search | What's New
|
